Journal
NATURE MEDICINE
Volume 15, Issue 4, Pages 380-383Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.1942
Keywords
-
Funding
- US National Institutes of Health [HL88635, HL71670, HL49989]
- American Heart Association Established Investigator Award [0840071N]
- Australian Research Council [DP0557780]
- New South Wales Health through Hunter Medical Research Institute
- Leducq Foundation [05CVD01]
- Alberta Heart and Stroke Foundation Chair
- Australian Research Council [DP0557780] Funding Source: Australian Research Council
Ask authors/readers for more resources
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal inherited arrhythmia syndrome in which drug therapy is often ineffective. We discovered that flecainide prevents arrhythmias in a mouse model of CPVT by inhibiting cardiac ryanodine receptor-mediated Ca2+ release and thereby directly targeting the underlying molecular defect. Flecainide completely prevented CPVT in two human subjects who had remained highly symptomatic on conventional drug therapy, indicating that this currently available drug is a promising mechanism-based therapy for CPVT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available